Goldline Pharmaceutical IPO Day 1 Subscription Status at 15.53x
By HDFC SKY | Published at: May 12, 2026 03:50 PM IST
Goldline Pharmaceutical IPO subscribed 15.53 times on Day 1 led by retail and NII demand.
Mumbai, May 12: Goldline Pharmaceutical IPO was subscribed 15.53 times on Day 1 of bidding on Tuesday, according to exchange data. The SME public issue received strong traction from retail and non-institutional investors.
The ₹11.61 crore book-built issue opened for subscription on May 12 and will close on May 14, 2026. The IPO is priced in the range of ₹41 to ₹43 per share and consists entirely of a fresh issue of 27 lakh shares. Goldline Pharmaceutical is proposed to be listed on the BSE SME platform.
Goldline Pharmaceutical IPO Day 1 Subscription Status
As of 2:49 PM on May 12, 2026, the IPO had been subscribed 15.53 times overall. The retail portion was booked 24.35 times, while the NII segment saw subscription of 14.86 times. The QIB category was subscribed 1.31 times.
| Category | Subscription (x) | Shares Offered | Shares Bid For |
| QIB (Ex Anchor) | 1.31 | 5,40,000 | 7,05,000 |
| NII | 14.86 | 3,90,000 | 57,96,000 |
| Retail Individual Investors | 24.35 | 9,00,000 | 2,19,12,000 |
| Total | 15.53 | 18,30,000 | 2,84,13,000 |
Category-wise Goldline Pharmaceutical IPO Subscription Status
| Investor Category | Subscription (x) |
| Retail Individual Investors | 24.35 |
| bNII (> ₹10 lakh) | 13.44 |
| sNII (< ₹10 lakh) | 17.64 |
| NII Overall | 14.86 |
| QIB (Ex Anchor) | 1.31 |
| Anchor Investors | 1.00 |
| Total Subscription | 15.53 |
Goldline Pharmaceutical IPO Day’s Wise Subscription Summary
The IPO opened for bidding on May 12 and witnessed healthy participation across investor categories on the first day itself. Retail investors led the demand, followed by the non-institutional investor segment.
| Date | QIB (Ex Anchor) | NII | Retail | Total |
| May 12, 2026 (Day 1) | 1.31x | 14.86x | 24.35x | 15.53x |
Goldline Pharmaceutical IPO Timeline
| Event | Date |
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Basis of Allotment | May 15, 2026 |
| Initiation of Refunds | May 18, 2026 |
| Credit of Shares | May 18, 2026 |
| Listing Date | May 19, 2026 |
Brief Overview Of The IPO
| Particulars | Details |
| Issue Size | ₹11.61 crore |
| Fresh Issue | 25,62,000 shares |
| Total Issue Size | 27,00,000 shares |
| Price Band | ₹41 to ₹43 per share |
| Lot Size | 3,000 shares |
| Minimum Retail Investment | ₹2,58,000 |
| Listing Exchange | BSE SME |
| Lead Manager | Cumulative Capital Pvt. Ltd. |
| Registrar | Bigshare Services Pvt. Ltd. |
Goldline Pharmaceuticals is engaged in the marketing of pharmaceutical products under the ‘Goldline’ brand. The company caters to multiple medical specialities including orthopaedics, gastroenterology, neurology, cardiology, paediatrics and general medicine through a diversified product portfolio.
Source:
- https://www.bseindia.com/markets/publicissues/displayipo?id=4573&type=IPO&idtype=1&status=L&IPONo=7716&startdt=12%2F05%2F2026
Disclaimer
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
